{
    "eid": "2-s2.0-85021658372",
    "title": "Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study",
    "cover-date": "2017-07-01",
    "subject-areas": [
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Pharmacology",
            "@code": "3004"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [
        "ABX464",
        "Human immunodeficiency virus"
    ],
    "authors": [
        "Jean Marc Steens"
    ],
    "citedby-count": 18,
    "ref-count": 21,
    "ref-list": [
        "Life expectancy living with HIV: Recent estimates and future implications",
        "Targeting HIV latency: Pharmacologic strategies toward eradication",
        null,
        "From reactivation of latent HIV-1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication",
        "Tissue reservoirs of HIV",
        "Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication",
        "J Acquir Immune Defic Syndr Clin Res",
        "Finding a cure for HIV: Will it ever be achievable?",
        "Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis",
        "Alternative splicing: Regulation of HIV-1 multiplication as a target for therapeutic action: Minireview",
        "How cells get the message: Dynamic assembly and function of mRNA-protein complexes",
        "HIV-1 Rev protein specifies the viral RNA export pathway by suppressing TAP/NXF1 recruitment",
        "Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects",
        "Randomized trial of food effect on pharmacokinetic parameters of ABX464 administered orally to healthy male subjects",
        "HIV reservoirs: What, where and how to target them",
        "Eradicating HIV-1 infection: Seeking to clear a persistent pathogen",
        "HIV reservoirs as obstacles and opportunities for an HIV cure",
        "Current status and prospects of HIV treatment",
        "The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells",
        "A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection",
        "Sci Rep"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Montpellier",
            "affilname": "Universit\u00e9 de Montpellier",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chicago",
            "affilname": "Northwestern University Feinberg School of Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Chiang Mai University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "Abivax",
            "affiliation-country": "France"
        }
    ],
    "funding": []
}